The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
Open accessAbstract
// Bo Cao 1,2,* , Yanfeng Qi 1,* , Guanyi Zhang 2,3 , Duo Xu 1,2 , Yang Zhan 1 , Xavier Alvarez 4 , Zhiyong Guo 5 , Xueqi Fu 2 , Stephen R. Plymate 6,7 , Oliver Sartor 8,9 , Haitao Zhang 2,3 , and Yan Dong 1,10 1 Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA 2 College of Life Sciences, Jilin University, China 3 Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA 4 Tulane National Primate Research Center, Covington, LA 5 Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 6 Departments of Medicine, University of Washington School of Medicine, Seattle, WA 7 Department of Urology, University of Washington School of Medicine, Seattle, WA 8 Department of Urology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA 9 Department of Medicine, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA 10 National Engineering Laboratory for AIDS Vaccine, College of Life Sciences, Jilin University, China * These authors contributed equally; in alphabetical order Correspondence: Yan Dong, Haitao Zhang, email: // Keywords : androgen receptor, splice variant, prostate cancer, castration resistance, enzalutamide Received : February 18, 2014 Accepted : March 2, 2014 Published : March 4, 2014 Abstract Upregulation of constitutively-active androgen receptor splice variants (AR-Vs) has been implicated in AR-driven tumor progression in castration-resistant prostate cancer. To date, functional studies of AR-Vs have been focused mainly on their ability to regulate gene expression independent of the full-length AR (AR-FL). Here, we showed that AR-V7 and AR v567es , two major AR-Vs, both facilitated AR-FL nuclear localization in the absence of androgen and mitigated the ability of the antiandrogen enzalutamide to inhibit AR-FL nuclear trafficking. AR-V bound to the promoter of its specific target without AR-FL, but co-occupied the promoter of canonical AR target with AR-FL in a mutually-dependent manner. AR-V expression attenuated both androgen and enzalutamide modulation of AR-FL activity/cell growth, and mitigated the in vivo antitumor efficacy of enzalutamide. Furthermore, AR v567es levels were upregulated in xenograft tumors that had acquired enzalutamide resistance. Collectively, this study highlights a dual function of AR-Vs in mediating castration resistance. In addition to trans-activating target genes independent of AR-FL, AR-Vs can serve as a “rheostat” to control the degree of response of AR-FL to androgen-directed therapy via activating AR-FL in an androgen-independent manner. The findings shed new insights into the mechanisms of AR-V-mediated castration resistance and have significant therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Self-citationWatson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
Cited by
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Androgen Signaling in Prostate Cancer
Dai, C., Heemers, H., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 406
Wilson, S., Qi, J., & Filipp, F. V. (2016) · Scientific Reports · doi:10.1038/srep32611 · Cited by 126
Impact of taxanes on androgen receptor signaling
Dong, Y., Bai, S., & Zhang, B. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_37_18 · Cited by 26
Self-citation
Metadata
- Authors
- Cao, B., Qi, Y., Zhang, G., Xu, D., Zhan, Y., Alvarez, X., Guo, Z., Fu, X., Plymate, S. R., Sartor, O., Zhang, H., & Dong, Y.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-03-04
- Volume
- 5
- Issue
- 6
- Pages
- 1646-1656
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1848444843
- Cited by
- 194
- References
- 5
- FWCI
- 22.05
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. https://app.cochat.ai/papers/10.18632/oncotarget.1802
- The paper
- Cao, B., Qi, Y., Zhang, G., Xu, D., Zhan, Y., Alvarez, X., Guo, Z., Fu, X., Plymate, S. R., Sartor, O., Zhang, H., & Dong, Y. (2014). Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget. https://doi.org/10.18632/oncotarget.1802
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.